SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Mercedes-Benz to Launch Advanced Urban Self-Driving System in the U.S., Challenging Tesla FSD 
Dell Revives XPS Laptop Lineup With New XPS 14 and XPS 16 to Boost Premium PC Demand 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Cathay Pacific Shares in Focus as Air China Plans Major Stake Reduction 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire 
China Reviews Meta’s $2 Billion AI Deal With Manus Amid Technology Control Concerns 
Nvidia Unveils Rubin Platform to Power Next Wave of AI Infrastructure 
BTIG Initiates Buy on SoftBank as AI and Robotics Strategy Gains Momentum 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
- SM04690 exhibited clinically meaningful and significant improvements in pain, function, and joint space width in unilateral symptomatic osteoarthritis patients -
- Samumed will be presenting data in three presentations at the 2017 ACR/ARHP Annual Meeting -
SAN DIEGO, Oct. 24, 2017 -- Samumed, LLC, today announces highlights from its 52-week Phase 2 proof-of-concept study of SM04690 in osteoarthritis (OA) of the knee, lending support to SM04690’s potential as a disease modifying osteoarthritis drug (DMOAD). In unilateral symptomatic knee OA patients, one of the three doses (0.07mg) of a single intra-articular injection of SM04690 showed clinically meaningful and significant improvements compared to placebo in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and function scores. In the same prespecified patient population, SM04690 potentially maintained or increased medial joint space width (mJSW) compared to placebo, where changes in mJSW were predictive of WOMAC pain and function improvement.
Similar trends were observed in the intent to treat (ITT) group, as well as in the other two doses studied. Detailed results from the 52-week study will be presented at the 2017 ACR/ARHP Annual Meeting being held on Nov. 3-8 in San Diego:
| Oral presentation | |||
| Presentation Title: | Results from a 52 Week Randomized, Double-Blind, Placebo- Controlled, Phase 2 Study of a Novel, Intra-Articular, Wnt Pathway Inhibitor (SM04690) for the Treatment of Knee Osteoarthritis | ||
| Presenter: | Yusuf Yazici, M.D. | ||
| Session Title: | Osteoarthritis – Clinical Aspects I: Structural Progression & Incidence | ||
| Date/Time: | Sunday, Nov. 5, at 5:30 p.m. PST | ||
| Abstract Number: | 935 | ||
| Poster presentations | |||
| Presentation Title: | Reducing Heterogeneity in OA Clinical Trials: Data from a Phase 2 Study of SM04690, a Novel, Intra-Articular, Wnt Pathway Inhibitor in Knee Osteoarthritis | ||
| Session Title: | Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions | ||
| Date/Time: | Monday, Nov. 6, from 9-11 a.m. PST | ||
| Abstract Number: | 1201 | ||
| Presentation Title: | Radiographic Outcomes Were Associated with Pain and Function Responses: Post-Hoc Analysis of Results from a Phase 2 Study of a Small Molecule Wnt Pathway Inhibitor, SM04690, for Knee Osteoarthritis Treatment | ||
| Session Title: | Osteoarthritis – Clinical Aspects Poster I: Clinical Trials and Interventions | ||
| Date/Time: | Monday, Nov. 6, from 9-11 a.m. PST | ||
| Abstract Number: | 1204 | ||
About SM04690
SM04690 is a small molecule inhibitor of the Wnt pathway administered as an intra-articular injection, and is being developed as a potential disease modifying drug for osteoarthritis (DMOAD). Preclinical data suggest SM04690 has a dual mechanism of action with three specific effects on joint health – generating new articular cartilage, slowing down cartilage degradation, and reducing inflammation in the joint. Additional information on Samumed’s SM04690 Osteoarthritis program can be found here:
https://www.samumed.com/pipeline/detail.aspx?id=20
About Samumed
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Samumed’s clinical pipeline can be found here: https://www.samumed.com/pipeline/default.aspx
Corporate Contact:
Erich Horsley
Samumed, LLC
[email protected]
858-365-0200
Investor Contact:
Ashley Robinson
LifeSci Advisors
[email protected]
617-535-7742
Media Contact:
Matt Middleman, M.D.
LifeSci Public Relations
[email protected]
646-627-8384
